← Back to Search

Not Applicable

LY3549492 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through final follow-up at approximately day 76
Awards & highlights

Summary

This trial is testing a new drug called LY3549492 to see if it is safe and tolerable for healthy people. Researchers will take blood samples to find out how much of the drug gets into the bloodstream and how the body handles it. The study will last for a few months for each participant.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through final follow-up at approximately day 76
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through final follow-up at approximately day 76 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Secondary study objectives
PK: Maximum Concentration (Cmax) of LY3549492
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3549492

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3549492 (Part B)Experimental Treatment1 Intervention
LY3549492 administered orally as multiple ascending doses.
Group II: LY3549492 (Part A)Experimental Treatment1 Intervention
LY3549492 administered orally as single ascending doses.
Group III: PlaceboPlacebo Group1 Intervention
Placebo administered orally.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3549492
2021
Completed Phase 1
~160

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,640 Previous Clinical Trials
3,221,590 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,358 Previous Clinical Trials
418,036 Total Patients Enrolled
~12 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top